Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT for Concurrent Type 2 Diabetes and Autoimmune Thyroid Disease
NCT07733232Phase 4Not yet recruiting
- Start
- Aug 2026
- Primary completion
- Dec 2027
01
Overview
Phase 4, open-label, single-arm trial of Fecal Microbiota Transplantation Capsule in type 2 diabetes mellitus (T2DM) and autoimmune thyroid disease (AITD). Primary endpoints: Glycated Hemoglobin at 24 weeks, Fasting blood glucose at 24 weeks and 3 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
type 2 diabetes mellitus (T2DM)autoimmune thyroid disease (AITD)
Beyond the preview
Go deeper on NCT07733232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07733232.